Showing 1 - 5 results of 5 for search 'Javier Salvador Bofill', query time: 0.03s Refine Results
  1. 1
    Early Myocardial Strain Reduction and miR-122-5p Elevation Associated with Interstitial Fibrosis in Anthracycline-Induced Cardiotoxicity

    Early Myocardial Strain Reduction and miR-122-5p Elevation Associated with Interstitial Fibrosis in Anthracycline-Induced Cardiotoxicity by María de Regla Caballero-Valderrama, Elisa Bevilacqua, Miriam Echevarría, Francisco Javier Salvador-Bofill, Antonio Ordóñez, José Eduardo López-Haldón, Tarik Smani, Eva M. Calderón-Sánchez

    Published 2024-12-01
    Get full text
    Article
  2. 2
    Predictive factors for complete pathologic response in luminal breast cancer: impact of ki67 and HER2 low expression

    Predictive factors for complete pathologic response in luminal breast cancer: impact of ki67 and HER2 low expression by Isabel Miras, Ana Gil, Marta Benavent, María Ángeles Castilla, Begoña Vieites, María Ángeles Dominguez-Cejudo, Sonia Molina-Pinelo, Lina Alfaro, Javier Frutos, Manuel Ruiz-Borrego, Alejandro Falcón, Mónica Cejuela, Javier Salvador-Bofill

    Published 2024-12-01
    Get full text
    Article
  3. 3
    Olaparib plus trastuzumab in HER2-positive advanced breast cancer patients with germline BRCA1/2 mutations: The OPHELIA phase 2 study

    Olaparib plus trastuzumab in HER2-positive advanced breast cancer patients with germline BRCA1/2 mutations: The OPHELIA phase 2 study by José Enrique Alés-Martínez, Judith Balmaña, Pedro Sánchez-Rovira, Francisco Javier Salvador Bofill, Jose Ángel García Sáenz, Isabel Pimentel, Serafín Morales, María Fernández-Abad, Ainhara Lahuerta Martínez, Neus Ferrer, Pilar Zamora, Begoña Bermejo, Tamara Díaz-Redondo, María Helena López-Ceballos, María Galán, Jhudit Pérez-Escuredo, Laura Calabuig, Miguel Sampayo, José Manuel Pérez-Garcia, Javier Cortés, Antonio Llombart-Cussac

    Published 2024-10-01
    Get full text
    Article
  4. 4
    Patritumab deruxtecan in HER2-negative breast cancer: part B results of the window-of-opportunity SOLTI-1805 TOT-HER3 trial and biological determinants of early response

    Patritumab deruxtecan in HER2-negative breast cancer: part B results of the window-of-opportunity SOLTI-1805 TOT-HER3 trial and biological determinants of early response by Fara Brasó-Maristany, Juan Manuel Ferrero-Cafiero, Claudette Falato, Olga Martínez-Sáez, Juan Miguel Cejalvo, Mireia Margelí, Pablo Tolosa, Francisco Javier Salvador-Bofill, Josefina Cruz, Blanca González-Farré, Esther Sanfeliu, Andreu Òdena, Violeta Serra, Francisco Pardo, Ana María Luna Barrera, Miriam Arumi, Juan Antonio Guerra, Guillermo Villacampa, Rodrigo Sánchez-Bayona, Eva Ciruelos, Martín Espinosa-Bravo, Yann Izarzugaza, Patricia Galván, Judith Matito, Sonia Pernas, Maria Vidal, Anu Santhanagopal, Dalila Sellami, Stephen Esker, Pang-Dian Fan, Fumitaka Suto, Ana Vivancos, Tomás Pascual, Aleix Prat, Mafalda Oliveira

    Published 2024-07-01
    Get full text
    Article
  5. 5
    Safety and efficacy of ribociclib plus letrozole in patients with HR+, HER2– advanced breast cancer: Results from the Spanish sub-population of the phase 3b CompLEEment-1 trial

    Safety and efficacy of ribociclib plus letrozole in patients with HR+, HER2– advanced breast cancer: Results from the Spanish sub-population of the phase 3b CompLEEment-1 trial by Javier Salvador Bofill, Fernando Moreno Anton, Cesar Augusto Rodriguez Sanchez, Elena Galve Calvo, Cristina Hernando Melia, Eva Maria Ciruelos Gil, Maria Vidal, Begoña Jiménez-Rodriguez, Luis De la Cruz Merino, Noelia Martínez Jañez, Rafael Villanueva Vazquez, Ruben de Toro Salas, Antonio Anton Torres, Isabel Manuela Alvarez Lopez, Joaquin Gavila Gregori, Vanesa Quiroga Garcia, Elena Vicente Rubio, Juan De la Haba-Rodriguez, Santiago Gonzalez-Santiago, Nieves Diaz Fernandez, Agusti Barnadas Molins, Blanca Cantos Sanchez de Ibargüen, Juan Ignacio Delgado Mingorance, Meritxell Bellet Ezquerra, Sonia de Casa, Asuncion Gimeno, Miguel Martin

    Published 2022-12-01
    Get full text
    Article

Search Tools: